form8k.htm
Standard
Industrial Classification Code 3826
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15 (D)
of
the
SECURITIES
EXCHANGE ACT OF 1934
Date of
Report (Date of earliest event reported): June 22, 2009
Arrayit
Corporation
(Formerly
Integrated Media Holdings, Inc.)
(Exact
name of registrant as specified in its charter)
NEVADA
(State or
other jurisdiction of incorporation or organization)
|
33-119586
|
76-0600966
|
|
(Commission
File Number)
|
(IRS
Employer Identification Number)
|
524 East
Weddell Drive
Sunnyvale,
CA 94089
(Address
of principal executive offices)
Rene
Schena
524 East
Weddell Drive
Sunnyvale,
CA 94089
(Name and
address of agent for service)
408-744-1711
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
|
o
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
o
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
o
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
o
|
Pre-commencement
communications pursuant to Rule 13e-4 (c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Effective
Thursday, June 22, 2009 Arrayit Corporation (OTC.BB: ARYC), a leading
manufacturer of products and services for disease prevention, treatment and
cure, announced today that its microarray-based diagnostic test, patented under
the trade name Variation Identification Platform (VIP), is ready for manufacture
and distribution. A breakthrough screening test using VIP will allow clinicians
and researchers to test and detect the H1N1 swine flu virus in population wide
studies.
ITEM
9.01 – Financial Statements and Exhibits
Press
Release
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
|
|
|
Arrayit
Corporation
|
|
|
|
|
|
|
|
|
|
|
Date: June
22, 2009
|
By:
/s/ Rene A.
Schena
|
|
|
Name:
Rene A. Schena
Title:
Chief Executive Officer
|
|
Arrayit
Corporation Addresses Flu Pandemic
Breakthrough
Technology Provides Population-Wide Screening
|
·
|
Source:
Arrayit Corporation
|
|
·
|
On
Thursday June 18, 2009, 7:00 am EDT
|
Arrayit
Corporation (OTC.BB: ARYC), a leading manufacturer of products and services for
disease prevention, treatment and cure, announced today that its
microarray-based diagnostic test, patented under the trade name Variation
Identification Platform (VIP), is ready for manufacture and distribution. A
breakthrough screening test using VIP will allow clinicians and researchers to
test and detect the H1N1 swine flu virus in population wide
studies.
The World
Health Organization (WHO) announced on June 11, that the threat level of the
H1N1 swine flu virus is now a global pandemic. This news is ideally timed with
Arrayit Corporation's release of its patented VIP screening test.
The
Arrayit test will allow researchers and clinicians to detect the presence of the
new H1N1 virus in mass numbers of flu patients, and to distinguish this
threatening mutated strain from less harmful variants. Arrayit's first supplies
will be sent to the Centers for Disease Control (CDC) in Atlanta to be approved
for use in the USA. Shortly thereafter, the H1N1 test kits will be made
available for emergency use by licensed clinics, laboratories and other health
care organizations worldwide.
The VIP
screening test is the first of its kind developed for multiple numbers of test
subjects, with diagnosis available to patients within hours of testing. Up to
80,000 patients can be screened at a time, making it possible for entire
communities and entire countries to quickly identify those infected with the new
H1N1 virus. The ability to test and quickly diagnose mass numbers of subjects
allows health clinicians the opportunity to gain control of the spread of the
virus in a shorter time frame than current individual testing procedures. The
VIP test kits will be made available at an affordable cost (estimated at under
$50 per individual), making it feasible even for those without health insurance
coverage to be screened.
About
Arrayit Corporation
Arrayit
Corporation, headquartered in Sunnyvale, California, leads and empowers the
genetic, research, pharmaceutical, and diagnostic communities through the
discovery, development and manufacture of proprietary life science technologies
and consumables for disease prevention, treatment and cure. It now offers over
650 products to a customer base of more than 2,500 laboratories worldwide,
including most every major university, pharmaceutical and biotech company, major
agricultural and chemical company, government agency, national research
foundation and many private sector enterprises. Please visit www.arrayit.com for
more information.
Safe
Harbor Statement
Except
for historical information contained herein, statements made in this release
that constitute forward-looking statements are based on currently available
information, involve certain risks and uncertainties and the Company assumes no
responsibility to update any such forward-looking statement. The following
factors, among others, may cause actual results to differ materially from the
results suggested in the forward-looking statements. Risks that may result from
changes in the Company's business operations; our ability to keep pace with
technological advances; significant competition in the biomedical business; our
relationships with key suppliers and customers; quality and consumer acceptance
of newly introduced products; market volatility; non-availability of product;
excess inventory; price and product competition; new product introductions, the
outcome of our legal disputes; the possibility that the review of our prior
filings by the SEC may result in changes to our financial statements; and the
possibility that stockholders or regulatory authorities may initiate proceedings
against Arrayit and/or our officers and directors as a result of any
restatements. Risk factors associated with our business, including some of the
facts set forth herein, are detailed in the Company's Form 10-K/A for the fiscal
year ended December 31, 2008 and Form 10-Q/A for the fiscal first quarter ended
March 31, 2009 and Form 10-Q/A for the fiscal third quarter ended September 30,
2008.
Contact:
Investor
Contact:
Arrayit
Corporation
Tel:
408-744-1331
Email:
investorinfo@arrayit.com
Web:
www.arrayit.com
Media
Contact:
Rod
Mitchell
Tel:
281-350-5506